0A55 Stock Overview
Provides diagnostic testing solutions. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
QuidelOrtho Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.25 |
| 52 Week High | US$75.38 |
| 52 Week Low | US$29.91 |
| Beta | 0.12 |
| 11 Month Change | -7.62% |
| 3 Month Change | -19.38% |
| 1 Year Change | -44.23% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -62.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A55 | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | -17.9% | 7.9% | -0.1% |
| 1Y | -44.2% | -2.0% | 5.5% |
Return vs Industry: 0A55 underperformed the UK Medical Equipment industry which returned -2% over the past year.
Return vs Market: 0A55 underperformed the UK Market which returned 5.5% over the past year.
Price Volatility
| 0A55 volatility | |
|---|---|
| 0A55 Average Weekly Movement | 6.5% |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A55 has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0A55's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 7,100 | Brian Blaser | www.quidelortho.com |
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.
QuidelOrtho Corporation Fundamentals Summary
| 0A55 fundamental statistics | |
|---|---|
| Market cap | US$2.43b |
| Earnings (TTM) | -US$1.87b |
| Revenue (TTM) | US$2.82b |
0.9x
P/S Ratio-1.3x
P/E RatioIs 0A55 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A55 income statement (TTM) | |
|---|---|
| Revenue | US$2.82b |
| Cost of Revenue | US$1.48b |
| Gross Profit | US$1.34b |
| Other Expenses | US$3.21b |
| Earnings | -US$1.87b |
Last Reported Earnings
Sep 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -27.75 |
| Gross Margin | 47.57% |
| Net Profit Margin | -66.25% |
| Debt/Equity Ratio | 80.5% |
How did 0A55 perform over the long term?
See historical performance and comparison